

Valerie G Brunton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6117951/publications.pdf>

Version: 2024-02-01

58
papers

3,781
citations

218381

26
h-index

155451

55
g-index

61
all docs

61
docs citations

61
times ranked

7535
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 1072-1090.	2.1	5
2	Use of SRS microscopy for imaging drugs. , 2022, , 403-419.		3
3	Characterisation of the Stromal Microenvironment in Lobular Breast Cancer. <i>Cancers</i> , 2022, 14, 904.	1.7	13
4	Chemical Interrogation of Nuclear Size Identifies Compounds with Cancer Cell Line-Specific Effects on Migration and Invasion. <i>ACS Chemical Biology</i> , 2022, 17, 680-700.	1.6	12
5	Cytoplasmic innate immune sensing by the caspase-4 non-canonical inflammasome promotes cellular senescence. <i>Cell Death and Differentiation</i> , 2022, 29, 1267-1282.	5.0	14
6	Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors. <i>Cancer Research</i> , 2022, 82, 632-647.	0.4	6
7	Characterisation of a nucleo-adhesome. <i>Nature Communications</i> , 2022, 13, .	5.8	4
8	The fibrotic and immune microenvironments as targetable drivers of metastasis. <i>British Journal of Cancer</i> , 2021, 124, 27-36.	2.9	47
9	Recent advances in the use of stimulated Raman scattering in histopathology. <i>Analyst, The</i> , 2021, 146, 789-802.	1.7	9
10	Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS. <i>Analytical Chemistry</i> , 2021, 93, 5862-5871.	3.2	25
11	A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. <i>Cancer Research</i> , 2021, 81, 5438-5450.	0.4	20
12	ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. <i>Oncogene</i> , 2021, 40, 6235-6247.	2.6	16
13	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. <i>Cancers</i> , 2021, 13, 5396.	1.7	17
14	HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 543-555.	1.1	28
15	Utilizing Stimulated Raman Scattering Microscopy To Study Intracellular Distribution of Label-Free Ponatinib in Live Cells. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2028-2034.	2.9	50
16	Characterisation of estrogen receptor alpha (ER α) expression in breast cancer cells and effect of drug treatment using targeted nanoparticles and SERS. <i>Analyst, The</i> , 2020, 145, 7225-7233.	1.7	9
17	Investigation of cellular uptake mechanism of functionalised gold nanoparticles into breast cancer using SERS. <i>Chemical Science</i> , 2020, 11, 5819-5829.	3.7	57
18	Novel roles of PRK1 and PRK2 in cilia and cancer biology. <i>Scientific Reports</i> , 2020, 10, 3902.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Alkyne-Tagged PLGA Allows Direct Visualization of Nanoparticles In Vitro and Ex Vivo by Stimulated Raman Scattering Microscopy. <i>Biomacromolecules</i> , 2019, 20, 4008-4014.	2.6	23
20	Kinetic analysis of bioorthogonal reaction mechanisms using Raman microscopy. <i>Faraday Discussions</i> , 2019, 220, 71-85.	1.6	3
21	Inhibition of cyclin-dependent kinase activity exacerbates H ₂ O ₂ -induced DNA damage in Kindler syndrome keratinocytes. <i>Experimental Dermatology</i> , 2019, 28, 1074-1078.	1.4	8
22	Development of a fluorescence-based cellular apoptosis reporter. <i>Methods and Applications in Fluorescence</i> , 2019, 7, 015001.	1.1	4
23	The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype. <i>Science Advances</i> , 2019, 5, eaaw0254.	4.7	93
24	Raman Imaging of Nanocarriers for Drug Delivery. <i>Nanomaterials</i> , 2019, 9, 341.	1.9	47
25	Development of mouse models of angiosarcoma driven by p53. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	12
26	Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2104-2110.	2.9	19
27	ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH ^{High} Melanoma-Initiating Cells. <i>Cell Chemical Biology</i> , 2018, 25, 1456-1469.e6.	2.5	43
28	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. <i>Scientific Reports</i> , 2018, 8, 15454.	1.6	55
29	The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. <i>Nature Cell Biology</i> , 2017, 19, 518-529.	4.6	748
30	Kindlin-1 protects cells from oxidative damage through activation of ERK signalling. <i>Free Radical Biology and Medicine</i> , 2017, 108, 896-903.	1.3	17
31	Imaging drug uptake by bioorthogonal stimulated Raman scattering microscopy. <i>Chemical Science</i> , 2017, 8, 5606-5615.	3.7	75
32	WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel. <i>Scientific Reports</i> , 2017, 7, 45255.	1.6	34
33	Mouse models of metastasis: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1061-1074.	1.2	216
34	Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth. <i>Cancer Research</i> , 2017, 77, 5301-5312.	0.4	48
35	Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy. <i>Oncotarget</i> , 2016, 7, 11539-11552.	0.8	27
36	Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4697-4710.	2.9	52

#	ARTICLE	IF	CITATIONS
37	AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3593-3608.	2.9	167
38	Kindlin1 regulates microtubule function to ensure normal mitosis. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 338-348.	1.5	23
39	ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival. <i>Cell Reports</i> , 2015, 13, 1949-1964.	2.9	70
40	In vivo imaging of the tumor and its associated microenvironment using combined CARS / 2-photon microscopy. <i>Intravital</i> , 2015, 4, e1055430.	2.0	33
41	Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. <i>DMM Disease Models and Mechanisms</i> , 2015, 9, 131-40.	1.2	9
42	Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. <i>Cell</i> , 2015, 163, 160-173.	13.5	304
43	The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer. <i>Biochemical Journal</i> , 2014, 463, 157-165.	1.7	21
44	Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor) Tyrosine Kinase Inhibitors. <i>Journal of Cellular Biochemistry</i> , 2014, 117, 50-64.	1.6	17
45	N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture. <i>Frontiers in Chemistry</i> , 2014, 2, 56.	1.8	22
46	Kindlin-1 regulates mitotic spindle formation by interacting with integrins and Plk-1. <i>Nature Communications</i> , 2013, 4, 2056.	5.8	36
47	Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. <i>Journal of Pathology</i> , 2013, 230, 430-440.	2.1	14
48	The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells. <i>International Journal of Cancer</i> , 2012, 131, 287-297.	2.3	52
49	Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. <i>Drug Discovery Today</i> , 2012, 17, 203-214.	3.2	18
50	Src Kinase Inhibitors: Promising Cancer Therapeutics?. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 145-159.	0.2	65
51	Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery. <i>Pharmaceutics</i> , 2011, 3, 141-170.	2.0	60
52	Two-color Photoactivatable Probe for Selective Tracking of Proteins and Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 11607-11616.	1.6	37
53	Quantitative <i>In vivo</i> Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics. <i>Cancer Research</i> , 2010, 70, 9413-9422.	0.4	122
54	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 246-251.	3.3	530

#	ARTICLE	IF	CITATIONS
55	Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3540-3549.	3.2	147
56	Src and focal adhesion kinase as therapeutic targets in cancer. <i>Current Opinion in Pharmacology</i> , 2008, 8, 427-432.	1.7	161
57	Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells. <i>Blood</i> , 2008, 112, 4222-4222.	0.6	0
58	Recent advances in the use of stimulated Raman scattering in histopathology. , 0, .		1